OncoMatch/Clinical Trials/NCT06956391
Ultralow Dose PET Imaging of 18F-FDG Uptake
Is NCT06956391 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies 18F-FDG for healthy volunteer.
Treatment: 18F-FDG — The goal of this clinical trial is to evaluate an investigational ultralow dose PET imaging technique for cancer detection and monitoring. The main question it aims to answer is: Can the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard? Participants will be injected with a radioactive tracer called 18F-FDG and be imaged on a new type of high-sensitivity PET scanner for up to 3 hours.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Demographics
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Nuclear Imaging Institute · Englewood, New Jersey
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06956391 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 120 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify